Compare EVO & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVO | PCRX |
|---|---|---|
| Founded | 1993 | 2006 |
| Country | Germany | United States |
| Employees | 4553 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 934.1M | 1.0B |
| IPO Year | N/A | 2010 |
| Metric | EVO | PCRX |
|---|---|---|
| Price | $2.73 | $22.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $7.00 | ★ $30.25 |
| AVG Volume (30 Days) | 95.9K | ★ 533.8K |
| Earning Date | 04-08-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 107.44 |
| EPS | N/A | ★ 0.07 |
| Revenue | N/A | ★ $541,533,000.00 |
| Revenue This Year | $1.37 | $6.78 |
| Revenue Next Year | $10.05 | $8.54 |
| P/E Ratio | ★ N/A | $324.86 |
| Revenue Growth | N/A | ★ 26.04 |
| 52 Week Low | $2.31 | $18.80 |
| 52 Week High | $4.80 | $27.64 |
| Indicator | EVO | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 41.07 | 40.41 |
| Support Level | $2.32 | $21.80 |
| Resistance Level | $3.78 | $24.20 |
| Average True Range (ATR) | 0.09 | 1.23 |
| MACD | -0.06 | -0.25 |
| Stochastic Oscillator | 19.16 | 5.58 |
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.